Cannabinoids in Bipolar Affective Disorder

Cannabinoids in Bipolar Affective Disorder: A Controlled Pilot Study

Some people with bipolar disorder who use cannabis (marijuana) claim that it eases the symptoms of depression and mania. There are many chemicals (called cannabinoids) found in cannabis but two particular ones appear to have medicinal (therapeutic) effects. These two compounds are: delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). These cannabinoids appear to have mood, anxiety, and sedative effects as well as have antipsychotic and anticonvulsant properties. This study will try to find out if these cannabinoids can be of benefit as an add-on treatment in bipolar disorder and what effects it has on thinking power and memory.

Study Overview

• Status: Withdrawn
• Conditions: Bipolar Affective Disorder
• Intervention / Treatment: Drug: Synthetic cannabinoids (1:1 ratio of THC % CBD)

Detailed Description

This study will be a within-subject, random order, double-blind cross-over study with standard clinical and neuropsychological ratings. Duration is 13 weeks per subject. Clinical assessments including mood ratings will be performed weekly. Instructions and practice on the use of the spray will be given under supervision during a 2-week run-in period before baseline. Patients can control the dosage of cannabinoids according to their symptoms by administering up to a maximum of 48 pump-controlled sprays per day. Patients will be asked to abstain from using cannabis (other than the study drug) during the study. Patients will be treated for 4 weeks with either the sublingual THC:CBD spray or placebo spray. This will be followed by a 2-week washout period before another 4 weeks of treatment with whichever study medication was not initially used. Neurocognitive testing will be performed 3 times during the study. A mood diary will be completed daily by each patient at home.

• Study Type: Interventional
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Canada
  • British Columbia
    • Vancouver, British Columbia, Canada, V6T 2A1
      • Department of Psychiatry, University of British Columbia

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 19 years to 60 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Outpatients between the 19-60 years of age with a diagnosis of bipolar disorder.
• Women must not be currently pregnant and must use a reliable method of contraception for the duration of the study.
• Subjects must be on stable medication (4 weeks minimum) for their bipolar illness (symptomatic despite current treatment), must be able to provide written informed consent, must adequately understand written and verbal English.

Exclusion Criteria:

• Those not meeting the inclusion criteria and those not able to give informed consent.
• Women who are currently pregnant or nursing.
• Those at immediate risk of harming self or others;
• those who have a clinically significant medical illness or other significant psychiatric illness;
• currently abusing alcohol or drugs;
• currently being treated with an investigational medication or medication that is contraindicated with cannabinoids;
• have a known allergy to cannabis-based products.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Double

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Crossover	Drug: Synthetic cannabinoids (1:1 ratio of THC % CBD); Randomized crossover study of 2 weeks of active study medication (maximum daily dosage of 60 mg) vs. 2 weeks of matching placebo.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
To determine whether a standardized plant extract of cannabis containing a 1:1 ratio of THC & CBD can alleviate bipolar mood symptoms unresponsive to standard treatment. To be measured weekly over 13 weeks.	13 weeks

Secondary Outcome Measures

Outcome Measure
To determine the effects on cognition.
To be measured at baseline and at the end of each treatment phase.

Collaborators and Investigators

• Sponsor: University of British Columbia
• Collaborators: Vancouver General Hospital
• Investigators: Principal Investigator: Allan H. Young, Ph.D, University of British Columbia

Study record dates

Study Major Dates

• Study Start: November 1, 2006
• Primary Completion (Anticipated): December 1, 2013
• Study Completion (Anticipated): December 1, 2013

Study Registration Dates

• First Submitted: November 7, 2006
• First Submitted That Met QC Criteria: November 8, 2006
• First Posted (Estimate): November 9, 2006

Study Record Updates

• Last Update Posted (Estimate): September 18, 2014
• Last Update Submitted That Met QC Criteria: September 16, 2014
• Last Verified: September 1, 2014

More Information

Terms related to this study

• Keywords: bipolar; cannabinoids; neurocognitive performance; therapeutic potential
• Additional Relevant MeSH Terms: Mental Disorders; Genetic Diseases, Inborn; Bipolar and Related Disorders; Bipolar Disorder; Mood Disorders; Genetic Diseases, X-Linked
• Other Study ID Numbers: H06-00239